X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. 90y Radioisotope
2. Y-90 Radioisotope
1. Yttrium Y-90
2. 10098-91-6
3. Yttrium Y 90
4. Yttrium (90 Y)
5. Y-90
6. 1k8m7ur6o1
7. Yttrium Radioisotopes
8. 90y
9. Sir-spheres
10. 90yttrium
11. Unii-1k8m7ur6o1
12. Yttrium, Isotope Of Mass 90
13. 90y Radioisotope
14. Radioactive Yttrium
15. Y-90 Radioisotope
16. Yttrium, Radioactive
17. Hsdb 7406
18. Dtxsid40874005
19. Yttrium (90 Y) [who-dd]
20. Db13076
21. Y 90
22. Q2650092
23. D015021000
| Molecular Weight | 89.907142 g/mol |
|---|---|
| Molecular Formula | Y |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 0 |
| Rotatable Bond Count | 0 |
| Exact Mass | 89.907142 g/mol |
| Monoisotopic Mass | 89.907142 g/mol |
| Topological Polar Surface Area | 0 Ų |
| Heavy Atom Count | 1 |
| Formal Charge | 0 |
| Complexity | 0 |
| Isotope Atom Count | 1 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Intraarterial injection of yttrium-90 microspheres (TheraSpheres) is used in the treatment of hepatocellular carcinoma (HCC). /Yttrium-90 microspheres/
PMID:15713921 Goin JE et al; J Vasc Interv Radiol 16(2 Pt 1): 205-13 (2005)
Yttrium-90 (90-Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%. This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with 90Y-ibritumomab tiuxetan treatment. MATERIALS AND METHODS: The medical records of patients (n=211) with relapsed, refractory, or transformed indolent CD20+ B-cell NHL who were treated with 90Y ibritumomab tiuxetan were reviewed. Time to progression (TTP) of > or =12 months was noted in 78 patients (37%), who were identified as long-term responders and were further characterized. RESULTS: Median age of the long-term responders was 58 years (range, 24-80 years) with 44% over 60 years, and 55% were male. Notably, 59% of patients had received > or =2 prior regimens, 33% had received > or =3 prior regimens, and 37% had failed to respond to immediate prior therapy. Median response duration was 28.1 months (range, 10.5-80.3+ months). Median TTP was 29.3 months (range, 12.1-81.5+ months). In patients with ongoing response, median TTP was 53.9 months (range, 49-82+ months). CONCLUSIONS: (90)Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL. Failure to respond to prior therapy does not preclude achieving a long-term response with 90Y ibritumomab tiuxetan. /Yttriium-90 ibritumomab tiuxetan/
PMID:15869453 Wiseman GA et al; Cancer Biother Radiopharm 20(2): 185-8 (2005)
/EXPTL THER/ 90Y-1,4,7,10-tetraazacyclododecane tetraacetic acid (90Y-DOTA) and 90Y-diethylene triamine pentaacetic acid (90Y-DTPA) complexes were studied for possible use in intra-vascular radionuclide therapy (IVRNT). 90Y was obtained from a 90Sr-90Y generator based on supported liquid membrane technique. The 90Y-DOTA and 90Y-DTPA complexes were prepared under optimised conditions. Bio-distribution of the complexes in Swiss mice showed that nearly 90% of 90Y complexes of both the ligands were excreted via urine within 1 h post-injection with negligible localisation in vital organs. Probenecid inhibition studies showed that both complexes are excreted by glomerular filtration. The predominant and quick excretion of 90Y-DOTA and 90Y-DTPA through the kidneys suggest that both these complexes could be explored for use in IVRNT. /Yttrium-90/
PMID:12201136 Pandey U et al; Appl Radiat Isot 57 (3): 313-8 (2002)
/EXPTL THER/ Radionuclide therapy with (90Y-DOTA,Tyr(3))octreotide started in 3 different phase I trials. Overall, antimitotic effects have been observed: about 20% partial response and 60% stable disease (n = 92) along with complete symptomatic cure of several malignant insulinoma and gastrinoma patients. /Yttrium-90/
PMID:11965608 De Jong M et al; Semin Nucl Med 32 (2): 133-40 (2002)
/EXPTL THER/ Peptide receptor-targeted radionuclide therapy of somatostatin receptor-expressing tumors is a promising application of radiolabeled somatostatin analogs. Suitable radionuclides are yttrium-90, a pure, high-energy beta-emitter (2.27 MeV), and lutitium-177, a medium-energy beta-emitter (0.5 MeV) with a low-abundance gamma. /Yttrium-90/
PMID:15653647 de Jong M et al; J Nucl Med 46 Suppl 1:13S-7S (2005)
Eighty-eight TheraSphere-treated patients with low 90-day mortality risk were selected for analysis, with liver toxicities coded with use of standard oncology criteria. Descriptive and inferential statistical methods were applied to estimate the incidence of liver toxicities and to evaluate the influence of liver radiation dose and various pretreatment factors on the risk of their occurrence. ... Sixty-eight liver toxicities occurred in 37 of the 88 patients (42%). Thirty-two patients (36%) experienced 50 liver toxicities after the first treatment and nine of 23 patients (39%) who received a second treatment experienced 18 liver toxicities. Pretreatment total bilirubin and liver radiation dose were found to be associated with the risk of at least one liver toxicity and with the time to first occurrence of a liver toxicity after first treatment. Pretreatment total bilirubin also was associated with liver toxicities after the second treatment. Most of the toxicities resolved; however, those that did not resolve were attributed to tumor progression or advancing cirrhosis... /Yttrium-90 microspheres/
PMID:15713921 Goin JE et al; J Vasc Interv Radiol 16(2 Pt 1): 205-13 (2005)
Peptide receptor-targeted radionuclide therapy is nowadays being performed with radiolabeled DOTA-conjugated peptides, such as (90Y-DOTA0,Tyr3)octreotide (also known as OctreoTher or 90Y-DOTATOC). The incorporation of 90Y3+ is typically > or = 99%, however, since a total patient dose can be as high as 26 GBq or 700 mCi the amount of free 90Y3+ (= non-DOTA-incorporated) can be substantial. Free 90Y3+ accumulates in bone with undesired radiation of bone marrow as a consequence. 90Y-DTPA is excreted rapidly via the kidneys. Incorporation of free 90Y3+ into 90Y-DTPA might prevent this fraction from being accumulated into bone, therefore we have investigated: the biodistribution in rats of 90YCl3, (90Y-DOTA0,Tyr3)octreotide, and 90Y-DTPA; possibilities to complex 10% of free 90Y3+ in a (90Y-DOTA0,Tyr3)octreotide containing solution into 90Y-DTPA prior to intravenous injection; and effects of 10% free 90Y3+ in (90Y-DOTA0,Tyr3)octreotide solution, in the presence and in the absence of excess DTPA, on the biodistribution of in rats. The following results are presented: 90YCl3 showed high skeletal uptake (i.e., 1% ID (injected dose) per gram femur, with main localization in the epiphyseal plates) and a 24 hr total body retention of 74% ID; 90Y-DTPA had rapid renal clearance, and 24 hr total body retention of < 5% ID; added free 90Y3+ in (90Y-DOTA0,Tyr3)octreotide solution could rapidly be incorporated into 90Y-DTPA at room temperature; and accumulation of 90Y3+ in femur, blood, and liver was related to the amount of free 90Y3+, whereas these accumulations could be prevented by the addition of DTPA. In conclusion, the addition of excess DTPA to (90Y-DOTA0,Tyr3)octreotide with incomplete 90Y-incorporation is recommended. /90Y-DPTATOC, yttrium-90 chloride/
PMID:15246375 Breeman WA et al; Nucl Med Biol 31 (6): 821-4 (2004)
The therapeutic effects of peptide receptor-based radionuclide therapy are extensively being investigated in rats bearing tumors. Both the dose to the tumor and the therapy-limiting dose to normal tissues, such as kidneys and bone marrow, are of interest for these preclinical studies. The aim of this work was to develop a generalized computational model for internal dosimetry in rats. METHODS: Mature rats were dissected and the relative positions, dimensions, and weights of all of their major organs were measured. A mathematic model was set up for the rat body and its internal organs to enable Monte Carlo radiation transport calculations to determine estimates for both tumor and organ self-doses as cross-organ doses for yttrium-90, indium-111, and lutitium-177. The organs and body were mostly of ellipsoid shape with the axes given as the measured length, width, and height normalized to values that, together with the measured weights, are consistent with the recommended soft-tissue and bone densities. A spheric tumor of 0.25 g was positioned on the right femur. Calculations were performed with the Monte Carlo neutral particle transport code MCNP for the beta-emitters (maximum energy, 2.28 MeV) and lutitium-177 (maximum energy, 0.497 MeV) and for the gamma-emissions from lutitium-177 and from indium-111. The presented absorbed dose S values are used to calculate the absorbed dose estimates for the rat organs in a study on the biodistribution of 177Lu-DOTA-Tyr(3)-octreotate (DOTA is 1,4,7,10-tetraazadodecane-N,N',N",N"'-tetraacetic acid). Three activity distributions were considered in the kidney: uniform in the whole kidney, in the cortex, or in the outer 1-mm-thick rim of the cortex. Isodose curves and dose volume histograms were calculated for the dose distribution to the kidneys. RESULTS: Depending on the activity distribution in the kidneys, the renal dose for 177Lu-DOTA-Tyr(3)-octreotate is 0.13-0.17 mGy/MBq. CONCLUSION: The renal dose of 70-95 Gy for an injected activity of 555 MBq will likely cause radiation damage, although the higher amount of peptide with this activity may influence the dosimetry by partial receptor saturation. Dose volume histograms show that indium-111 and lutitium-177 are likely to have a higher threshold for renal damage than yttrium-90. /177-Lu, 111-In, and 90-Y/
PMID:15235075 Konijnenberg MW et al; J Nucl Med 45 (7): 1260-9 (2004)
Market Place
